Gene: Pla2g16 (phospholipase A2, group XVI) Rattus norvegicus | ![]() Analyze |
![]() |
Annotation (Toggle Annotation Detail/Summary View) |

![]() |
Create Name: | |
Description: |
![]() |
Save what matters to you |
{{ loginError }} |
Sign in with your RGD account |
Create New Account | Recover Password |
![]() Functional Annotation unavailable |
![]() Annotation Distribution unavailable |
![]() Genomic Variants unavailble for Mouse Genomic Variants unavailable |
Functional Annotation |
Annotation Distribution |
Genomic Variants |
![]() Protein-Protein Interactions unavailable |
![]() Genome Viewer unavailable |
![]() Damaging Variants unavailble for Mouse Damaging Variants unavailable |
Protein-Protein Interactions |
Genome Viewer |
Damaging Variants |
![]() Annotation Comparison unavailable |
![]() OLGA unavailable |
![]() |
Annotation Comparison |
OLGA |
Excel (Download) |
![]() Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-catechin | multiple interactions | ISO | RGD:737532 | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of PLA2G16 mRNA | CTD | PMID:24763279 | (R)-lipoic acid | decreases expression | ISO | RGD:734412 | 6480464 | Thioctic Acid results in decreased expression of PLA2G16 mRNA | CTD | PMID:22941773 | (R)-lipoic acid | decreases activity | ISO | RGD:734412 | 6480464 | Thioctic Acid results in decreased activity of PLA2G16 protein | CTD | PMID:22941773 | (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE | increases expression | EXP | | 6480464 | Topotecan results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:734412 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PLA2G16 mRNA | CTD | PMID:21354282 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:737532 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of PLA2G16 mRNA | CTD | PMID:20106945 more ... | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PLA2G16 mRNA | CTD | PMID:21215274 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2,4-dinitrotoluene affects the expression of PLA2G16 mRNA | CTD | PMID:21346803 | 3,3',5,5'-tetrabromobisphenol A | decreases expression | EXP | | 6480464 | tetrabromobisphenol A results in decreased expression of PLA2G16 mRNA | CTD | PMID:27914987 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | RGD:734412 | 6480464 | N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PLA2G16 mRNA | CTD | PMID:26251327 | 3-chloropropane-1,2-diol | increases expression | EXP | | 6480464 | alpha-Chlorohydrin results in increased expression of PLA2G16 mRNA | CTD | PMID:28522335 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:737532 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLA2G16 mRNA; more ... | CTD | PMID:28628672 | 4-amino-2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 4-amino-2,6-dinitrotoluene affects the expression of PLA2G16 mRNA | CTD | PMID:21346803 | 6-propyl-2-thiouracil | decreases expression | EXP | | 6480464 | Propylthiouracil results in decreased expression of PLA2G16 mRNA | CTD | PMID:24780913 | amiodarone | increases expression | ISO | RGD:734412 | 6480464 | Amiodarone results in increased expression of PLA2G16 mRNA | CTD | PMID:24535564 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of PLA2G16 mRNA | CTD | PMID:16483693 | belinostat | multiple interactions | ISO | RGD:737532 | 6480464 | [NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G16 mRNA | CTD | PMID:27188386 | benzo[a]pyrene | increases expression | ISO | RGD:737532 | 6480464 | Benzo(a)pyrene results in increased expression of PLA2G16 mRNA | CTD | PMID:22316170 | bisphenol A | increases expression | ISO | RGD:734412 | 6480464 | bisphenol A results in increased expression of PLA2G16 mRNA | CTD | PMID:26063408 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of PLA2G16 mRNA | CTD | PMID:25181051 | bisphenol F | multiple interactions | ISO | RGD:737532 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLA2G16 mRNA | CTD | PMID:28628672 | cadmium dichloride | decreases expression | ISO | RGD:734412 | 6480464 | Cadmium Chloride results in decreased expression of PLA2G16 mRNA | CTD | PMID:18974090 | cadmium dichloride | decreases expression | ISO | RGD:737532 | 6480464 | Cadmium Chloride results in decreased expression of PLA2G16 mRNA | CTD | PMID:26472689 | carbon nanotube | decreases expression | ISO | RGD:734412 | 6480464 | Nanotubes, Carbon analog results in decreased expression of PLA2G16 mRNA; more ... | CTD | PMID:25554681 | catechin | multiple interactions | ISO | RGD:737532 | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of PLA2G16 mRNA | CTD | PMID:24763279 | ciguatoxin CTX1B | affects expression | ISO | RGD:734412 | 6480464 | Ciguatoxins affects the expression of PLA2G16 mRNA | CTD | PMID:18353800 | cisplatin | affects expression | ISO | RGD:737532 | 6480464 | Cisplatin affects the expression of PLA2G16 mRNA | CTD | PMID:23300844 | cisplatin | increases expression | ISO | RGD:737532 | 6480464 | Cisplatin results in increased expression of PLA2G16 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | RGD:737532 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of PLA2G16 mRNA | CTD | PMID:27392435 | copper(II) sulfate | decreases expression | ISO | RGD:737532 | 6480464 | Copper Sulfate results in decreased expression of PLA2G16 mRNA | CTD | PMID:19549813 | cyclosporin A | decreases expression | ISO | RGD:737532 | 6480464 | Cyclosporine results in decreased expression of PLA2G16 mRNA | CTD | PMID:20106945 PMID:25562108 | dexamethasone | increases expression | ISO | RGD:737532 | 6480464 | Dexamethasone results in increased expression of PLA2G16 mRNA | CTD | PMID:25047013 | dexamethasone | multiple interactions | ISO | RGD:737532 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLA2G16 mRNA; more ... | CTD | PMID:28628672 | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of PLA2G16 mRNA | CTD | PMID:21266533 | dicrotophos | decreases expression | ISO | RGD:737532 | 6480464 | dicrotophos results in decreased expression of PLA2G16 mRNA | CTD | PMID:28302478 | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of PLA2G16 mRNA | CTD | PMID:21551480 PMID:25152437 | dorsomorphin | multiple interactions | ISO | RGD:737532 | 6480464 | [NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G16 mRNA; more ... | CTD | PMID:27188386 | elemental selenium | increases expression | ISO | RGD:737532 | 6480464 | Selenium results in increased expression of PLA2G16 mRNA | CTD | PMID:19244175 | entinostat | increases expression | ISO | RGD:737532 | 6480464 | entinostat results in increased expression of PLA2G16 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | RGD:737532 | 6480464 | [NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G16 mRNA | CTD | PMID:27188386 | enzyme inhibitor | multiple interactions | ISO | RGD:737532 | 6480464 | [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of PLA2G16 protein | CTD | PMID:23301498 | ethanol | multiple interactions | EXP | | 6480464 | [Fish Oils co-treated with Ethanol] results in increased expression of PLA2G16 mRNA | CTD | PMID:17347304 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of PLA2G16 mRNA | CTD | PMID:24136188 | indole-3-methanol | affects expression | EXP | | 6480464 | indole-3-carbinol affects the expression of PLA2G16 mRNA | CTD | PMID:21396975 | indometacin | multiple interactions | ISO | RGD:737532 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLA2G16 mRNA; more ... | CTD | PMID:28628672 | ketamine | increases expression | EXP | | 6480464 | Ketamine results in increased expression of PLA2G16 mRNA | CTD | PMID:20080153 | L-ascorbic acid | multiple interactions | ISO | RGD:737532 | 6480464 | [Quercetin co-treated with Ascorbic Acid] results in increased expression of PLA2G16 mRNA | CTD | PMID:17639512 | lead(0) | affects expression | ISO | RGD:737532 | 6480464 | Lead affects the expression of PLA2G16 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:737532 | 6480464 | Lead affects the expression of PLA2G16 mRNA | CTD | PMID:28903495 | lipoic acid | decreases expression | ISO | RGD:734412 | 6480464 | Thioctic Acid results in decreased expression of PLA2G16 mRNA | CTD | PMID:22941773 | lipoic acid | decreases activity | ISO | RGD:734412 | 6480464 | Thioctic Acid results in decreased activity of PLA2G16 protein | CTD | PMID:22941773 | lipopolysaccharide | increases expression | ISO | RGD:734412 | 6480464 | Lipopolysaccharides results in increased expression of PLA2G16 mRNA | CTD | PMID:27339419 | mono(2-ethylhexyl) phthalate | increases expression | ISO | RGD:734412 | 6480464 | mono-(2-ethylhexyl)phthalate results in increased expression of PLA2G16 mRNA | CTD | PMID:22401849 | N-nitrosodiethylamine | decreases expression | ISO | RGD:734412 | 6480464 | Diethylnitrosamine results in decreased expression of PLA2G16 mRNA | CTD | PMID:18691550 | N-nitrosodiethylamine | decreases expression | EXP | | 6480464 | Diethylnitrosamine results in decreased expression of PLA2G16 mRNA | CTD | PMID:19638242 | N-nitrosodiethylamine | multiple interactions | ISO | RGD:734412 | 6480464 | IKBKB protein inhibits the reaction [Diethylnitrosamine results in decreased expression of PLA2G16 mRNA]; more ... | CTD | PMID:17942915 PMID:18691550 | N-nitrosodiethylamine | increases expression | ISO | RGD:734412 | 6480464 | Diethylnitrosamine results in increased expression of PLA2G16 mRNA | CTD | PMID:17942915 | nefazodone | decreases expression | EXP | | 6480464 | nefazodone results in decreased expression of PLA2G16 mRNA | CTD | PMID:24136188 | nickel atom | decreases expression | ISO | RGD:737532 | 6480464 | Nickel results in decreased expression of PLA2G16 mRNA | CTD | PMID:25583101 | nickel sulfate | increases expression | ISO | RGD:737532 | 6480464 | nickel sulfate results in increased expression of PLA2G16 mRNA | CTD | PMID:16780908 PMID:22714537 | nimesulide | decreases expression | EXP | | 6480464 | nimesulide results in decreased expression of PLA2G16 mRNA | CTD | PMID:24136188 | ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of PLA2G16 mRNA | CTD | PMID:23358140 | oxaliplatin | increases expression | EXP | | 6480464 | oxaliplatin results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | paracetamol | decreases expression | ISO | RGD:737532 | 6480464 | Acetaminophen results in decreased expression of PLA2G16 mRNA | CTD | PMID:29067470 | perfluorooctane-1-sulfonic acid | decreases expression | EXP | | 6480464 | perfluorooctane sulfonic acid results in decreased expression of PLA2G16 mRNA | CTD | PMID:18692542 | piperonyl butoxide | decreases expression | EXP | | 6480464 | Piperonyl Butoxide results in decreased expression of PLA2G16 mRNA | CTD | PMID:22484513 | pirinixic acid | decreases expression | ISO | RGD:734412 | 6480464 | pirinixic acid results in decreased expression of PLA2G16 mRNA | CTD | PMID:17426115 | pirinixic acid | increases expression | ISO | RGD:734412 | 6480464 | pirinixic acid results in increased expression of PLA2G16 mRNA | CTD | PMID:18301758 more ... | progesterone | increases expression | EXP | | 6480464 | Progesterone results in increased expression of PLA2G16 mRNA | CTD | PMID:20726854 | propiconazole | decreases expression | ISO | RGD:734412 | 6480464 | propiconazole results in decreased expression of PLA2G16 mRNA | CTD | PMID:21278054 | quercetin | multiple interactions | ISO | RGD:737532 | 6480464 | [Quercetin co-treated with Ascorbic Acid] results in increased expression of PLA2G16 mRNA | CTD | PMID:17639512 | quercetin | increases expression | ISO | RGD:737532 | 6480464 | Quercetin results in increased expression of PLA2G16 mRNA | CTD | PMID:21632981 | resveratrol | multiple interactions | EXP | | 6480464 | [resveratrol co-treated with Streptozocin] results in increased expression of PLA2G16 mRNA | CTD | PMID:25905778 | rotenone | increases expression | ISO | RGD:737532 | 6480464 | Rotenone results in increased expression of PLA2G16 mRNA | CTD | PMID:29955902 | SB 431542 | multiple interactions | ISO | RGD:737532 | 6480464 | [NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G16 mRNA; more ... | CTD | PMID:27188386 | selenium atom | increases expression | ISO | RGD:737532 | 6480464 | Selenium results in increased expression of PLA2G16 mRNA | CTD | PMID:19244175 | sodium arsenate | decreases expression | ISO | RGD:737532 | 6480464 | sodium arsenate results in decreased expression of PLA2G16 mRNA | CTD | PMID:12727804 | sodium arsenite | decreases expression | ISO | RGD:737532 | 6480464 | sodium arsenite results in decreased expression of PLA2G16 mRNA | CTD | PMID:12727804 | sodium arsenite | affects expression | ISO | RGD:737532 | 6480464 | sodium arsenite affects the expression of PLA2G16 mRNA | CTD | PMID:29319823 | sodium arsenite | increases expression | ISO | RGD:737532 | 6480464 | sodium arsenite results in increased expression of PLA2G16 mRNA | CTD | PMID:22714537 | streptozocin | multiple interactions | EXP | | 6480464 | [resveratrol co-treated with Streptozocin] results in increased expression of PLA2G16 mRNA | CTD | PMID:25905778 | Tesaglitazar | decreases expression | EXP | | 6480464 | tesaglitazar results in decreased expression of PLA2G16 mRNA | CTD | PMID:21515302 | tetrachloromethane | affects expression | ISO | RGD:734412 | 6480464 | Carbon Tetrachloride affects the expression of PLA2G16 mRNA | CTD | PMID:17484886 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of PLA2G16 mRNA | CTD | PMID:23411599 | tipifarnib | increases expression | EXP | | 6480464 | tipifarnib results in increased expression of PLA2G16 mRNA | CTD | PMID:16403772 | titanium dioxide | affects expression | ISO | RGD:734412 | 6480464 | titanium dioxide affects the expression of PLA2G16 mRNA | CTD | PMID:23557971 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of PLA2G16 mRNA | CTD | PMID:25729387 | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of PLA2G16 mRNA | CTD | PMID:21515302 | tunicamycin | increases expression | ISO | RGD:737532 | 6480464 | Tunicamycin results in increased expression of PLA2G16 mRNA | CTD | PMID:22378314 | valproic acid | increases expression | ISO | RGD:734412 | 6480464 | Valproic Acid results in increased expression of PLA2G16 mRNA | CTD | PMID:24535564 | valproic acid | increases expression | ISO | RGD:737532 | 6480464 | Valproic Acid results in increased expression of PLA2G16 mRNA | CTD | PMID:19101580 more ... | valproic acid | multiple interactions | ISO | RGD:737532 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G16 mRNA | CTD | PMID:27188386 | vitamin E | increases expression | ISO | RGD:737532 | 6480464 | Vitamin E results in increased expression of PLA2G16 mRNA | CTD | PMID:19244175 | |
|
|
|
|
|
|
|
|
|
|
1. | Hajnal A, etal., Oncogene 1994 Feb;9(2):479-90. |
2. | Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7 |
3. | Longati P, etal., Oncogene 1994 Jan;9(1):49-57. |
4. | NCBI rat LocusLink and RefSeq merged data July 26, 2002 |
5. | RGD automated data pipeline |
6. | RGD automated import pipeline for gene-chemical interactions |
7. | RGD comprehensive gene curation |
8. | Sers C, etal., J Cell Biol. 1997 Feb 24;136(4):935-44. |
9. | Siegrist S, etal., Oncogene. 2001 Aug 23;20(37):5155-63. |
10. | Uyama T, etal., J Lipid Res. 2009 Apr;50(4):685-93. doi: 10.1194/jlr.M800453-JLR200. Epub 2008 Dec 1. |
Pla2g16 has been annotated in the following RGD Disease Portals. |
|||||
![]() |
| ||||
![]() |
| ||||
![]() |
| ||||
![]() |
| ||||
![]() |
| ||||
![]() |
|
Pla2g16 (Rattus norvegicus - Norway rat) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PLA2G16 (Homo sapiens - human) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pla2g16 (Mus musculus - house mouse) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PLA2G16 (Pan paniscus - bonobo/pygmy chimpanzee) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PLA2G16 (Canis lupus familiaris - dog) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pla2g16 (Ictidomys tridecemlineatus - thirteen-lined ground squirrel) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PLA2G16 (Sus scrofa - pig) |
|
RH142176 |
|
The following QTLs overlap with this region. | ![]() | Full Report | ![]() | CSV | ![]() | TAB | ![]() | Printer | ![]() | Gviewer |
The detailed report is available here: | ![]() | Full Report | ![]() | CSV | ![]() | TAB | ![]() | Printer |
miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/). For more information about miRGate, see PMID:25858286 or access the full paper here. |
RefSeq Transcripts | NM_017060 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
XM_006230687 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
GenBank Nucleotide | AABR07006119 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
AABR07006120 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AAHX01009367 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AAHX01009368 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AB298805 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
CB613004 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
CB794299 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
CH473953 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
FQ224126 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
RefSeq Acc Id: | NM_017060 ⟹ NP_058756 | ||||||||||||||||||||||||
RefSeq Status: | VALIDATED | ||||||||||||||||||||||||
Type: | CODING | ||||||||||||||||||||||||
Position: |
|
||||||||||||||||||||||||
Sequence: |
AGAGTTTTTTCTGGGACCTAAACAAAGGCATCCACGGCGCTGCTAAGCTGAAGTTGAGCCTCAChide sequence |
RefSeq Acc Id: | XM_006230687 ⟹ XP_006230749 | ||||||||||||||
RefSeq Status: | |||||||||||||||
Type: | CODING | ||||||||||||||
Position: |
|
||||||||||||||
Sequence: |
AGTCATGTGCCACCAAGCCAGGCCTTACTGCCTCTTGATCTGAGCTTGACAGCTGGGACTCTCThide sequence |
Protein RefSeqs | NP_058756 | (Get FASTA) | NCBI Sequence Viewer |
XP_006230749 | (Get FASTA) | NCBI Sequence Viewer | |
GenBank Protein | BAH08634 | (Get FASTA) | NCBI Sequence Viewer |
EDM12684 | (Get FASTA) | NCBI Sequence Viewer | |
EDM12685 | (Get FASTA) | NCBI Sequence Viewer | |
P53817 | (Get FASTA) | NCBI Sequence Viewer |
RefSeq Acc Id: | NP_058756 ⟸ NM_017060 |
- UniProtKB: | P53817 (UniProtKB/Swiss-Prot) |
- Sequence: |
MPIPEPKPGDLIEIFRPMYSHWAIYVGDGYVIHLAPPSEIPGAGAASIMSALTDKAIVKKELLRhide sequence |
RefSeq Acc Id: | XP_006230749 ⟸ XM_006230687 |
- Peptide Label: | isoform X1 |
- Sequence: |
MPHCLSYHWDTQIQAGLWQSAVMAAGQPLRPWPEPKPGDLIEIFRPMYSHWAIYVGDGYVIHLAhide sequence |
RGD ID: | 13690722 | |||||||||
Promoter ID: | EPDNEW_R1247 | |||||||||
Type: | initiation region | |||||||||
Name: | Pla2g16_1 | |||||||||
Description: | phospholipase A2, group XVI | |||||||||
SO ACC ID: | SO:0000170 | |||||||||
Source: | EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/) | |||||||||
Experiment Methods: | Single-end sequencing. | |||||||||
Position: |
|
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
Database | Acc Id | Source(s) |
Ensembl Genes | ENSRNOG00000021206 | ENTREZGENE, UniProtKB/Swiss-Prot |
Ensembl Protein | ENSRNOP00000038045 | ENTREZGENE, UniProtKB/Swiss-Prot |
ENSRNOP00000068660 | UniProtKB/TrEMBL | |
Ensembl Transcript | ENSRNOT00000032879 | ENTREZGENE, UniProtKB/Swiss-Prot |
ENSRNOT00000090872 | UniProtKB/TrEMBL | |
InterPro | IPR007053 | UniProtKB/Swiss-Prot |
KEGG Report | rno:24913 | UniProtKB/Swiss-Prot |
NCBI Gene | 24913 | ENTREZGENE |
Pfam | PF04970 | UniProtKB/Swiss-Prot |
PhenoGen | Pla2g16 | PhenoGen |
UniGene | Rn.11377 | ENTREZGENE |
UniProt | A0A0G2JTD0_RAT | UniProtKB/TrEMBL |
P53817 | ENTREZGENE, UniProtKB/Swiss-Prot | |
UniProt Secondary | B7X6T2 | UniProtKB/Swiss-Prot |
Date | Current Symbol | Current Name | Previous Symbol | Previous Name | Description | Reference | Status |
---|---|---|---|---|---|---|---|
2008-10-16 | Pla2g16 | phospholipase A2, group XVI | Hrasls3 | HRAS like suppressor 3 | Nomenclature updated to reflect human and mouse nomenclature | 1299863 | APPROVED |
2006-03-30 | Hrasls3 | HRAS like suppressor 3 | HRAS like suppressor | Name updated | 1299863 | APPROVED | |
2003-12-05 | Hrasls3 | HRAS like suppressor | Hrev107 | Symbol updated | 61478 | APPROVED | |
2002-11-06 | Hrasls3 | HRAS like suppressor | Hrev107 | Hras-revertant gene 107 | Symbol and Name updated | 625702 | APPROVED |
2002-06-10 | Hrev107 | Hras-revertant gene 107 | Symbol and Name status set to approved | 70586 | APPROVED |
Note Type | Note | Reference |
---|---|---|
gene_cellular_localization | localizes to both cell membrane and cytoplasm | 708597 |
gene_expression | specifically expressed in H-ras resistant fibroblasts | 708597 |
gene_protein | molecular weight of 18 kDa | 708597 |
More on Pla2g16 | |
![]() |
Alliance Gene |
![]() |
NCBI Gene |
![]() |
Ensembl Gene |
![]() |
JBrowse: rn5 rn6 |
![]() |
NCBI Genome Data Viewer |
RGD Object Information | |
RGD ID: | 2829 |
Created: | 2000-05-25 |
Species: | Rattus norvegicus |
Last Modified: | 2019-01-30 |
Status: | ACTIVE |
© Medical College of Wisconsin
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.